Advanced, multi-target assay design
with RNase P human sample confirmation

Thermo Fisher Scientific continues to provide the gold standard of testing with our evolved, PCR-based TaqPath RNase P Combo Kit 2.0 test, which was established to help laboratories quickly diagnose COVID-19 caused by SARS-CoV- 2 infection.

TaqPath RNase P Combo Kit 2.0 was developed with an advanced, multi-target assay design and RNase P control for human sample confirmation.

TaqPath COVID-19 RNase P Combo Kit 2.0—Now available!

Features:

  • Recommended for use with RNA extracted from nasopharyngeal and anterior nasal swabs
  • Detects active infections from individuals suspected of COVID-19 by their healthcare provider, as well as asymptomatic individuals
  • Utilizes human sample confirmation RNase P gene as an internal control
  • Go from sample to result in ~3 hours

Fill out the form, and a sales representative will be in touch.

For Emergency Use Authorization. For in vitro diagnostics. For Prescription use only. Regulatory requirements vary by country. Product may not be available in your geographic region. © 2021 Thermo Fisher Scientific, Inc.

All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

*
*
*
*
*
*
 본 개인정보를 Life Technologies 그룹에 제공하는 것에 대해 동의하십니까?*
 Life Technologies 그룹에서 발송하는 이메일 수신에 동의 하십니까?

이 사이트는 reCAPTCHA에 의해 보호되며 Google 개인정보 처리방침서비스 약관이 적용됩니다.